ClinicalTrials.gg
RecruitingNCT05933057ULYSSESUpdated Jul 24, 2026

Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

A Phase 3 interventional study of Givinostat and Placebo in Duchenne Muscular Dystrophy, sponsored by Italfarmaco. Recruiting at 29 sites in 12 countries. Open to male participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Italfarmaco · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
9 Years to 17 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Muscular Dystrophy, Duchenne with a site in Italy — 19 open to participants now, 26 under way, 7 of them phase 3. Muscular Dystrophy, Duchenne · Italy.

Planned enrollment
23rd of 67
138 · median 73
Started
2024
with 4 others
Phase 3
24 of 82
3 open now
Primary completion
2028-02
later than 15 of 25 live
Registered
63rd of 82
by date
Lead sponsor
6 of 82
Italfarmaco

Among the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy, this one is the 23rd largest by planned enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2024, is one of 24 in phase 3, reaches primary completion later than 15 of the 25 other live ones, and was the 63rd registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

19 of the 82 studies in Muscular Dystrophy, Duchenne with a site in Italy are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 9 Years to 17 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Muscular Dystrophy, Duchenne with a site in Italy, or all of them as a file.
02

Study summary

This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to \<18 years) patients with DMD. 138 patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months.

  • Planned screening duration: approximately 4 weeks (±14 days)
  • Planned treatment duration: 18 months (approximately 72 weeks)
  • Planned follow-up duration: 4 weeks (±7 days) (for patients not participating in the long-term safety study)
  • Total duration of study participation: up to 83 weeks (ie, 20-21 months)
Read the detailed description

Duchenne muscular dystrophy is a rare, progressive, debilitating and life-threatening condition for which there is a critical need for novel therapies that are effective and well-tolerated in all DMD patients. Steroids are generally recognised as the standard of care in the general DMD population; however, they are not suitable for all patients.

Givinostat, a HDAC inhibitor, was developed for the treatment of DMD based on: (i) the role that increased HDAC activity is thought to exert in contributing to DMD pathogenesis; and (ii) givinostat's ability to counter the pathophysiological and degenerative mechanisms causing muscle insufficiency in boys with DMD.

This study will evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant patients to further corroborate data from the completed phase 3 pivotal study of givinostat in ambulant patients with DMD (ie, Study DSC/14/2357/48, NCT02851797). Primary Objective of the study is to demonstrate the efficacy of givinostat in reducing muscle decline in non-ambulant DMD patients, as measured by Performance of the Upper Limb (PUL) 2.0. Secondary Objectives of the study are to evaluate the safety and tolerability of givinostat in non-ambulant DMD patients, and to further explore the efficacy of givinostat in non-ambulant DMD patients.

A total of 138 patients are planned for enrolment. Patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months.

The study will be comprised of:

  • A screening period, during which eligibility will be confirmed within 4 weeks (±14 days)
  • A baseline visit, during which randomisation will be performed
  • A double-blind treatment period, during which patients will receive either givinostat or placebo for 18 months (approximately 72 weeks)
  • An end of study visit, occurring at Week 72 (±7 days) at the end of the treatment period. At the end of study visit, all the patients (regardless of treatment arm) will be offered enrolment in the long-term safety study DSC/14/2357/51 (NCT03373968) during which they will receive givinostat.
  • A follow-up visit, for those patients not consenting to participation in the long-term safety study, that will occur 4 weeks after the end of study visit (ie, Week 76 ±7 days).
03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne Muscular Dystrophy
  • givinostat
04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must satisfy all the following criteria:

  1. Children and adolescent males aged ≥ 9 to \<18 years at screening (patients ≥ 18 years of age at screening will not be enrolled into the study)
  2. Are able to give informed assent and/or consent in writing signed by the patient and/or parent/legal guardian (according to local regulations)
  3. A genetic diagnosis of DMD
  4. Non-ambulant, defined as being wheelchair bound and:

    1. Unable to perform the 10-meter walk/run test (10MWT), or
    2. Unable to complete the 10MWT in 30 seconds or less, without any support or devices
  5. Performance of the Upper Limb test (PUL version 2.0) entry item scores 3 to 6
  6. If on medication for DMD-associated cardiomyopathy (eg, ACE inhibitor, β-blocker, diuretics), stable for ≥1 month immediately prior to start of study treatment, if any
  7. Stable , defined as:

    1. Receiving systemic corticosteroids for a minimum of 6 months immediately prior to start of study treatment
    2. No significant change in dose or dosing regimen (except for adjustments due to body weight change) for a minimum of 6 months immediately prior to start of study treatment
  8. Willing to use adequate . Effective contraceptive methods must be used from randomisation visit through 3 months after the last dose of study drug, and include the following:

    1. True abstinence (ie, absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, post-ovulation, and symptothermal methods) and withdrawal are not acceptable methods of contraception
    2. Condom with spermicide and the female partner must use an effective method of contraception, such as an oral, transdermal, injectable or implanted hormonal contraceptive; intrauterine device; bilateral tubal occlusion, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such as for example cervical cap with spermicide jelly.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study if they satisfy any of the following criteria:

  1. Exposure to another drug within 3 months prior to start of study treatment.
  2. Have exposure to any dystrophin restoration product (eg, Ataluren, Exon skipping) within 6 months prior to the start of study treatment
  3. Having received any gene therapy (eg, AAV Micro-dystrophin delivery) prior to start of study treatment
  4. Use of any pharmacologic treatment or supplement (other than ), that might have had an effect on muscle strength or function within 3 months prior to the start of study treatment (eg, growth hormone); vitamin D, calcium and any other supplements will be allowed
  5. Use of testosterone, unless used as a replacement therapy for the treatment of delayed puberty. The testosterone dose and regimen should be stable within 6 months prior to the start of study treatment, and circulating testosterone levels should be within the normal ranges for the patient's age
  6. Elbow-flexion contractures >30° in the dominant arm
  7. Inability to perform consistent PUL 2.0 measurement within ±2 points without shoulder domain or within ±3 points with shoulder domain during paired testing at screening
  8. Forced Vital Capacity % of predicted \<40%
  9. Requirement for daytime ventilator assistance (Note: Night ventilator assistance and use of bi-level positive airway pressure therapy is allowed)
  10. Episode of respiratory failure within the 8 weeks prior to screening
  11. Symptomatic cardiomyopathy or heart failure and/or \<45%
  12. Baseline interval using Fredericia's formula (QTcF) >450 msec (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (eg, heart failure, hypokalaemia, or family history of long QT syndrome)
  13. Major surgical procedure (including scoliosis surgery) planned within 1 year of the start of study treatment
  14. Poorly controlled asthma or underlying lung disease such as bronchitis, bronchiectasis, emphysema, recurrent pneumonia that in the opinion of the Investigator might impact respiratory function
  15. , white blood cells, and/or \< lower limit of normal (LLN) at screening (Note: for abnormal screening laboratory test results [\<LLN], the platelets count, white blood cell, and haemoglobin will be repeated once; if the repeat test result is still \<LLN, the patient should be excluded)
  16. Fasting triglycerides >300 mg/dL (3.42 mmol/L) at screening (Note: if the value is >300 mg/dL, the triglycerides will be repeated once; if the repeated test result is still >300 mg/dL, the patient should be excluded)
  17. Current or history of liver disease or impairment, including but not limited to a baseline elevated total (ie, >1.5 × [ULN]), unless secondary to Gilbert disease or pattern consistent with Gilbert disease
  18. Inadequate renal function, as defined by serum Cystatin C result >2 × ULN (Note: if the value is >2 × ULN, the serum Cystatin C will be repeated once; if the repeated test result is still >2 × ULN, the patient should be excluded)
  19. Positive test for surface antigen, antibody, or at screening
  20. to any component of study medication
  21. Sorbitol intolerance or malabsorption, or have the hereditary form of fructose intolerance
  22. Diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD, based on Investigator judgement
  23. Psychiatric illness or social situations rendering the potential patient unable to understand and comply with the muscle function tests and/or with the study protocol procedures, based on Investigator judgement
  24. Have to MRI scan (eg, claustrophobia, metal implants, or uncontrolled seizure disorder), based on Investigator's judgement.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Givinostat

    Patients will receive concomitant corticosteroid treatment as part of the standard of care.

    Drug: Givinostat

  • Placebo comparator
    Placebo

    Patients will receive concomitant corticosteroid treatment as part of the standard of care.

    Drug: Placebo

Interventions

  • Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.

    Also known as: ITF2357

  • DrugPlacebo

    Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.

06

What researchers measure

Primary outcomes

  1. Change of Performance of Upper Limb 2.0 (PUL) total score at 18 months of treatment of givinostat compared to placebo group.

    The PUL examines 3 major "dimensions" of upper extremity function: shoulder, middle, and distal functions. It includes 22 scored items; a score of 42 (12 for shoulder; 17 for mid-level, and 13 for distal) indicates the highest level of independent function and 0 the lowest.

    Time frame: Baseline and 18 months

Secondary outcomes

  1. Change from baseline of Peak Expiratory Flow percent predicted (PEF%p) at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  2. Change from baseline of Forced Vital Capacity percent predicted (FVC%p) at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  3. Cumulative loss of PUL total score over 18 months of treatment of givinostat compared to placebo group.

    Time frame: Baseline to 18 months

  4. Type, incidence, and severity of treatment-emergent adverse events

    Time frame: Baseline to 18 months

  5. Proportion of patients experiencing treatment-emergent adverse events

    Time frame: Baseline to 18 months

  6. Change from baseline vital signs and clinical laboratory tests

    Time frame: Baseline and 18 months

  7. Change from baseline electrocardiogram and echocardiogram

    Time frame: Baseline and 18 months

  8. Time to assisted ventilation and rate of respiratory infection including duration, severity of respiratory infection and use of antibiotics, of givinostat compared to placebo group.

    Time frame: Baseline to 18 months

Other outcomes

  1. Change from baseline of Fat Fraction of Deltoid and Biceps brachii using Dixon technique at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  2. Proportion of responders of givinostat compared to placebo group

    Responders are defined as patients who did not change their baseline PUL entry score at the EOS

    Time frame: Baseline to 18 months

  3. Change from baseline of shoulder, elbow and distal level domains of PUL at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  4. Change from baseline in muscle strength (eg, elbow flexion) evaluated by hand held myometry at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  5. Change from baseline in grip strength of dominant hand as measured by Jamar Smart Hand dynamometer at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  6. Change from baseline in physical function as measured by Egen Klassifikation (EK) score at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  7. Change from baseline as measured by Motor Function Measure (MFM) at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  8. Change from baseline of Peak Cough Flow (PCF) at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  9. Age at loss of hand-to-mouth function assessed by PUL

    Time frame: Baseline to 18 months

  10. Age at loss of turn in bed ability assessed by EK

    Time frame: Baseline to 18 months

  11. Change from baseline in DMD Upper Limb Patient-Reported Outcome Measures questionnaire scores at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  12. Change from baseline in quality of life (as measured by Paediatric Quality of Life Inventory 4.0 Generic Core and 3.0 Neuromuscular Module) at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  13. Change from baseline in reports of activities of daily living (as measured by Barthel index) at 18 months of treatment of givinostat compared to placebo group

    Time frame: Baseline and 18 months

  14. Pharmacokinetic/Pharmacodynamic Endpoints

    PK parameters including, but not limited to, Cmax, T1/2, and AUC, will be assessed using sparse sampling. PD parameters will include PUL, FVC, PEF, MFM, and muscle strength

    Time frame: Baseline and 18 months

07

Study locations

19 of 29 sites recruiting
  • Universitaire Ziekenhuizen Leuven
    Leuven, 3000, Belgium
    Recruiting
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
    Recruiting
    • · ContactNmartic3@cw.bc.ca · 604-875-2345
    • Kathryn Selby, MD · Principal investigator
  • The University of Western Ontario - Children's Health Research Institute
    London, Ontario N6A 5W9, Canada
    Recruiting
  • University of Ottawa - Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
    Recruiting
  • University of Toronto - Holland Bloorview Kids Rehabilitation Hospital
    Toronto, Ontario M4G 1R8, Canada
    Recruiting
  • Klinika dětské neurologie 2. LF, Fakultní nemocnice v Motole
    Prague, 15006, Czechia
    Not yet recruiting
  • Centre Hospitalier Régional Universitaire de Lille
    Lille, 59037, France
    Recruiting
  • Centre hospitalier universitaire - Hôpitaux de Marseille
    Marseille, 13385, France
    Recruiting
  • Hôpital Armand-Trousseau - I-Motion
    Paris, 75935, France
    Recruiting
  • Charite-Universitaetsmedizin Berlin
    Berlin, 10117, Germany
    Recruiting
  • Universitätsklinikum Essen Kinder-und Jugendmedizin Neuropadiatrie
    Essen, 45147, Germany
    Not yet recruiting
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, 53113, Germany
    Recruiting
  • Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Kinder- und Jugendmedizin
    Hamburg, 20246, Germany
    Not yet recruiting
  • Associazione La Nostra Famiglia - IRCCS Eugenio Medea - Bosisio Parini
    Lecco, 23842, Italy
    Recruiting
  • Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscular Omnicentre
    Milan, 20162, Italy
    Recruiting
  • Università degli Studi di Padova - Azienda Ospedaliera di Padova
    Padova, 35128, Italy
    Recruiting
  • Ospedale Pediatrico Bambino Gesù
    Roma, 00165, Italy
    Recruiting
  • Policlinico Universitario Agostino Gemelli - Università Cattolica del Sacro Cuore
    Roma, 00165, Italy
    Recruiting
  • Leids Universitair Medisch Centrum (LUMC)
    Leiden, 2300 RC, Netherlands
    Recruiting
  • Radboud Universitair Medisch Centrum (Radboudumc)
    Nijmegen, 6500 HB, Netherlands
    Recruiting
  • Uniwersyteckie Centrum Kliniczne, Klinika Neurologii Rozwojowej
    Gdansk, 80952, Poland
    Not yet recruiting
  • Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny
    Warsaw, 02097, Poland
    Not yet recruiting
  • Clinic of Neurology and Psychiatry for Children and Youth
    Belgrade, 11000, Serbia
    Not yet recruiting
  • Hospital Sant Joan de Déu
    Barcelona, 08950, Spain
    Recruiting
  • Hospital Universitario y Politécnico La Fe
    Valencia, 46026, Spain
    Recruiting
  • Karolinska University Hospital, Solna CKB Centrum för Kliniska Barnstudier
    Stockholm, 17176, Sweden
    Not yet recruiting
  • Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University
    Newcastle upon Tyne, England NE1 3BZ, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Oxford University Hospitals NHS Foundation Trust
    Oxford, England OX3 9DU, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • NHS Greater Glasgow and Clyde - Royal Hospital for Children
    Glasgow, Scotland G51 4TF, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Bettica P, Petrini S, D'Oria V, D'Amico A, Catteruccia M, Pane M, Sivo S, Magri F, Brajkovic S, Messina S, Vita GL, Gatti B, Moggio M, Puri PL, Rocchetti M, De Nicolao G, Vita G, Comi GP, Bertini E, Mercuri E. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2016 Oct;26(10):643-649. doi: 10.1016/j.nmd.2016.07.002. Epub 2016 Jul 11. PubMed 27566866 ↗
  • Consalvi S, Mozzetta C, Bettica P, Germani M, Fiorentini F, Del Bene F, Rocchetti M, Leoni F, Monzani V, Mascagni P, Puri PL, Saccone V. Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med. 2013 May 20;19(1):79-87. doi: 10.2119/molmed.2013.00011. PubMed 23552722 ↗
  • Mercuri E, Vilchez JJ, Boespflug-Tanguy O, Zaidman CM, Mah JK, Goemans N, Muller-Felber W, Niks EH, Schara-Schmidt U, Bertini E, Comi GP, Mathews KD, Servais L, Vandenborne K, Johannsen J, Messina S, Spinty S, McAdam L, Selby K, Byrne B, Laverty CG, Carroll K, Zardi G, Cazzaniga S, Coceani N, Bettica P, McDonald CM; EPIDYS Study Group. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024 Apr;23(4):393-403. doi: 10.1016/S1474-4422(24)00036-X. PubMed 38508835 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2028, 48 months after the start.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jul 6, 2023
StartActual
Feb 19, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05933057
Lead sponsor
Italfarmaco
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Feb 19, 2024
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Jul 24, 2026

Study contacts

Italfarmaco Patient Advocacy
Contact
patientadvocacy@italfarmacogroup.com
+39 02 6443 1

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion